Oncology

We have four programmes in the oncology sector of our pipeline. Two of these candidates are already successfully partnered with Novartis, one with Chroma Therapeutics whilst the other is a recent addition to the pipeline, arising out of our own research.

Oncology pipeline

Programmes

Product	Indication	Late Research	Pre-Clinical	Phase I	Phase II	Phase III	Marketed	Marketing Rights	Peak Sales
AUY922	Cancer							Novartis	$$$
CHR2797	Cancer							Chroma Therapeutics	$$
HSP990	Cancer							Novartis	$$
V158411	Cancer							Worldwide	$$

Key

Unpartnered programmes
Partnered programmes
Peak sales: $: < $150m $$: $150-$500m $$$: $500m+

Oncology targets

Amenable to our expertise

The research and development techniques we have pioneered, especially our expertise in fragment-based drug discovery, are particularly well suited to the types of molecular target that cancer presents. It’s this kind of research that gave rise to V158411, one of the latest arrivals in our pipeline. We also have two priority programmes in partnership with Novartis, and one with cancer specialists Chroma Therapeutics.

Oncology has long been an area of focus for Vernalis, with many types of cancer still poorly treated with inadequate drugs. Vernalis conducts original research in the field, both in our own right, and with partner organisations. The two programmes currently in development with Novartis arose out of one such research collaboration.

Latest News